CHALLENGE:

The client wanted to evaluate the Phesi analytics approach (data and integrated analytical methods spanning patient, protocol and sites) that consistently leads to superior country and investigator site selection in a T2DM setting.

SOLUTION:

Phesi’s Trial Accelerator™ platform, driven by the world’s largest trial database, was used to: 

  • Assess the operational impact from key protocol design elements on enrollment cycle time, country and investigator site selection. 
  • Identify top enrolling investigator sites based on enrollment contribution and site activation performance scores.
  • Critically appraise investigator site recommendations from the CRO and other industry data providers and demonstrate for 7 trials the significant underperformance (based on site activation and enrollment measures) of the chosen sites compared to the sites nominated using the Phesi platform. 

THE DATA:

IMPACT:

Phesi demonstrated significantly improved investigator site selection approaches in T2DM. Based on this analysis Phesi generated a business case to significantly reduce FTE and annual feasibility operational costs by $10-15M.

 

Request a demo and find out how Phesi can help
you achieve smarter trials and faster cures

 

 

 

Related cases
03. 14. 2023
Protocol Design, Country and Investigator Site Selection: NSCLC Read more
03. 14. 2023
Protocol Optimization and Study Feasibility: Iron Overload Integrated Development Plan, Phase 1B Trial Read more
03. 14. 2023
Protocol Planning: Inotuzumab Ozogamicin In Acute Lymphoblastic Leukemia (ALL) Read more
03. 14. 2023
Protocol Design and Investigator Site Selection: Phase III Osteoarthritis Pain of the Knee Trial Read more
03. 06. 2023
Protocol Design and Investigator Site Selection: Follicular Lymphoma Read more